Toward a common therapeutic framework in castration-resistant prostate cancer: A model for urologic oncology and medical oncology interaction
White RD, Lara PN Jr. Urol Oncol. 2013 Dec 5. pii: S1078-1439(13)00383-9. doi: 10.1016/j.urolonc.2013.09.010. [Epub ahead of print]

Author information

University of California Davis Comprehensive Cancer Center, Sacramento, CA.


BACKGROUND: The rapid evolution of palliative therapeutic choices in the last few years for patients with advanced castration-resistant prostate cancer (CRPC) has resulted in a dilemma currently troubling a few other epithelial malignancies: which systemic agent to choose and at what time? In addition, which specialty specifically directs the delivery of such care-Urology or Medical Oncology-has not been clearly established.

APPROACH: Recognizing the lack of consensus, we propose a framework for Urology and Medical Oncology interactions that is founded on models that have succeeded in the past.

CONCLUSION: This approach aims to focus the care on the patient with CRPC rather than on his physicians and promises to improve patient outcomes in this disease state.